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Patients and methods. In ONCOSUR and CROASA between January 2010 and December 2012 we have treated 16 patients (50%
female) with 45 brain metastases and mean age of 53.63 years (33–68). A total of 21 treatments have been performed. Our GTV
margin was of 2–3mm. We have evaluated clinical, therapeutic data and acute toxicity.
Results. Primary tumorswere 7 breasts, 3melanomas, 5 lungs, and 1 esophagus. Only 6 patientswere also treatedwithwhole brain
radiotherapy (WBRT). The radiotherapy techniques used were: 15 Volume Modulated Arc Therapy (VMAT); 1 Intense Modulated
Therapy Step and Shoot (IMRT S-S); 1 Dynamic Arc Therapy (DART); and 4 3D Conformal Radiotherapy (3DCRT). The hipofrac-
tionated schemes more used were: 6Gy×6 fx (4 cases) and 10Gy×3 fx (6 cases). All patients received 2 fx per week. A variable
positioning accuracy of 1–4 mm has been reported for frameless stereotactic systems. In our series, IGRT repositioning mean
accuracy was: X=0.18 mm (0.01–0.44); Y=0.23mm (0.06–0.66); and Z=0.20mm (0.01–0.40). Acute side effects were not detected.
With a mean follow-up of 10.35 months (2–30), 6 patients are alive, and 10 are died. The causes of death were progression in:
brain 2 patients (no WBRT); lung 3 patients; liver 1 patient; unknown 3 patients and general deterioration 1 patient.
Conclusions. Frameless SRS is an effective and comfortable treatment in the management of brain metastases. Non-invasive mask
ﬁxation system plus IGRT is associated with a high repositioning accuracy with no errors up to 3mm.
http://dx.doi.org/10.1016/j.rpor.2013.03.540
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Objective. Craniopharingyoma is a sellar region neoplasm. Although histologically benign, it may cause visual and endocrino-
logical alterations and it has tendency to develop cysts and a high recurrence rate, representing a clinical challenge. Treatment is
not standardized. Therapeutic options being open or transsphenoidal surgery, cyst drainage, external or intralesional radiation
therapy and radiosurgery, even chemotherapy. To achieve better tumor control and reduce iatrogenesis (panhypopituitarism,
optic pathway lesion, hypothalamic lesion), there is a tendency towards management with surgery followed by irradiation of the
remaining tumor, treatment that is superior to surgery alone. We present our experience with Gamma-Knife radiosurgery as the
radiation treatment of choice.
Methods and patients. A retrospective review of the 49 cases of craniopharyngioma treated between 1993 and 2010 has been
performed. 16 of those patients were children (age under 15 years). Mean age was 32 years (ranged: 3–69). Forty four cases had
undergoneoneor variousprevious surgeries. 6 patientshad receivedprevious radiation therapyand1had received chemotherapy.
In 8 patients a stereotactic drainage of cysts was performed in concomitance with radiosurgery. Clinically, 26 patients had
hormonal alterations and 46 patients had visual symptoms.
Results. After an average follow-up of 45 months. 4 patients needed further treatment (surgery or chemotherapy) and only
1 experienced tumor progression in the long term. 97% of the patients showed clinical improvement or stabilization. Visual
impairments tend to improve, whether immediately or subsequently, while hormonal alterations usually persist. In 17% cyst
drainage was necessary to improve delayed worsening of visual impairment without solid tumor progression.
Conclusion. In the context of a multi-disciplinary approach to craniopharyngioma, Gamma-Knife radiosurgery offers excellent
long-term tumor control, without the signiﬁcant side-effects of other treatments. The results we present are comparable and add
further experience to other published series. Gamma-Knife radiosurgery is a simple and well tolerated technique with results
that can be reproduced worldwide and without interference with other procedures that may be necessary during the course of
the disease.
http://dx.doi.org/10.1016/j.rpor.2013.03.541
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Introduction. Three techniques have been developed to reduce SBRT toxicity: tracking, gating and diaphragmatic compression.
eXaCradle changes that paradigm.
Purpose. The eXaCradle reduces SBRT movements. We want to show the high precision SBRT using eXaCradle, slow-CT and
ConeBeamCT.
Methods and materials. We work with eXaCradle that combines 8 points of compression that give an enormous quantity of degrees
of freedom to customize the compression of every patient, to every tumor. The following procedure is carried out: (a) A Slow-CT of
patient inside the eXaCradle is acquired without any type of compression and in free breathing. (b) On the movement blurring the
combination of compressions most according to the manufacturer recommendations is decided. (c) A new Slow-CT* is acquired.
(d) A third hold breathing CT is acquired. (e) Organs at risk and tumor must be contouring on the third CT. (f) The third CT and the
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Slow-CT* are fused. Around the tumor will appear its movement blurring, it is the ITV. (g) We design treatment on the Slow-CT*.
(h) In the ConeBeamCT the tumor blurring must not exceed the PTV. (i) Patient is treated on Elekta-Synergy linac. (j) After every
treatment we repeat the acquisition IGRT and check the modiﬁcations during the treatment.
Results. Up to date a total of 10 patients have been treated, 9 primary tumors and a local relapse: 3–5 sessions and 40–50Gy dose
range. CT/PET images show complete response in 8 patients after 6 months. There were no G3 pneumonitis and no G2 esophagus
toxicity. The systematic error of intra-fraction movements were 0.4mm, 0.5mm and 0.9mm (x,y,z) and the random error were
0.5mm, 0.5mm and 1mm (x,y,z). Only in one patient the treatment time exceeded 12min.
Conclusions. ExaCradel and ConeBemaCT form a precise and rapid system as SBRT technology.
http://dx.doi.org/10.1016/j.rpor.2013.03.542
Hypothalamic hamartomas: Clinical experience in 23 cases treated with Gamma-Knife surgery
N. Martínez Moreno1, N. Lorite Díaz2, E. Kusak1, R. Martínez Álvarez1
1 Hospital Ruber Internacional, Unidad de Radiocirugía, Spain
2 Hospital Universitario de Girona Doctor Josep Trueta, Sevicio de Neurocirugia, Spain
Hypothalamic hamartomas (HH) arise as a result of an incorrect embryonic cell migration. Most patients with a HH are asymp-
tomatic. Gelastic seizures in association with HH were described some years ago and the majority of these patients present
medically refractory epilepsy. They can develop a severe epileptic encephalopathy associated to behavior and cognitive disor-
ders and precocious puberty (related to secretory granules). Surgery can be an effective treatment but it has been related to
important morbidity and mortality because of their location and relation to critical structures (optical pathways). The objective
of the present study is to evaluate our results with Gamma-Knife surgery (GKS) treatment in these lesions. Methods. We have
treated by GKS 30 patients with HH from 2002 to nowadays. We retrospectively reviewed our prospectively collected data and
analyze 23 of these patients. This series includes 14 women and 9 men, presenting lesions from 8cc to 0.2 cc. Mean age was 17
years old (ranged: 16 months to 45 years). For diagnosis and planning Video-EEG, CT and stereotactic MRI (T1, T2, Flair and T1
post-gadolinium, using axial, coronal and sagittal sections) were used.
Results. 8 cases had been operated previously. The mean coverage dose has been 18.5Gy. More than 70% of the patients had
a positive outcome, even though most of them still need medication. After 2 years follow-up, 5 cases were re-treated due to
medically refractory symptom persistence or reappearance. The mean coverage dose used was 17Gy. In 2 of these 5 patients a
favorable evolution was observed.
Conclusions. In the treatment and control of medically refractory epilepsy secondary to HH we considered GKS as an effective,
safe and reliable option. Prognostic factors that should be considered are evolution time (the precocity of treatment) and other
epileptic focus absence. Other factors are lesion size and relation-distance between the HH and the critical structures. The
possibility of achieving a correct coverage dose of more than 17Gy irradiating the entire lesion depends of them. These facts
have been conﬁrmed in our series.
http://dx.doi.org/10.1016/j.rpor.2013.03.543
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Objective. LINAC-based radiosurgery is commonly used for trigeminal neuralgia treatment. Due to the small size and spherical
or elliptical geometry of the target, small cones are suitable for this technique.
Materials and methods. A radiosurgery cone set (Brainlab) of diameter 5, 6, 7.5 and 10mm was modelled for a 6MV linac PRIMUS
(Siemens). Reference dose was measured using a camera PTW Farmer type 30013. Output factor, PDDs and OARs were measured
for each cone in a PTW water phantom MP3 using a diode detector PTW 60012. Correction in output factors is up to 6% for the
cone of 5mm. For commissioning the TPS: accuracy of monitor units (MU) calculations, isocentre localization, punctual dose
with MOSFET, and dose proﬁles with Gafchromics ﬁlms.
Results. We performed several veriﬁcations: (1) Manual calculation of MU performed with measured data shows a maximum
difference of 1.3%. (2) We used a Gafchromic EBT2 placed in the stereotactic localizer with a pin to locate isocentre. After a CT
scan, pin delineated and used like isocentre to deliver the treatment. Isocentre localization was less than 0.5mm. (3) We scanned
an anthropomorphic Alderson Rando phantom head with a MOSFET detector placed inside. We localized the CT scan using
iPLan, marked the isocentre at the MOSFET and delivered treatment. The dose agreement was for the 10-mm cone, lesser than
5% (MOSFET uncertainty: 3%). (4) A ﬁlm was placed at depth of 15mm in a water phantom and an arc of 120◦ was delivered. We
compared measured data with TPS calculation using OmniPro® (IBA). A good agreement is showed for inplane and crossplane.
